← 홈

프로그램 비교

타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일

현재 선택: 1개 · 임상 갱신 필요 1개

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

프로그램 선택

API CSV26행 · 1개 프로그램
OverviewMoAPK/PDToxicologyClinical

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목
CGTStandard DatabasestalePhase 2
bb2121 (Ide-cel, Ide-cel (bb2121))
Bristol-Myers Squibb·Multiple Myeloma
33 trials
Overview
Program
Ide-cel (bb2121)
Overview
Company
Bristol-Myers Squibb
Overview
Modality
CGT
Overview
Target
Multiple Myeloma
Overview
Indication
Multiple Myeloma
Overview
Phase
PHASE_2
Overview
Status
RECRUITING
Overview
Content status
Standard Database
Overview
Data Confidence
Data Confidence · Medium
Overview
Development Signal
Development Signal · Emerging
Overview
Approval status
Investigational
MoA
Mechanism
and may retain efficacy in this difficult setting
MoA
Biomarker
BCMA-targeted products exhibited high
PK/PD
Animal (cat.)
Unknown
PK/PD
Experiment
pharmacokinetic
Toxicology
Animal (cat.)
Unknown
Toxicology
Major finding
thrombocytopenia (P =
Toxicology
CRS
Reported
Clinical
Safety signal
thrombocytopenia (P =
Clinical
Selected reported efficacy
ORR 74.5%
Clinical
Reported ORR
34.3%
Clinical
Reported PFS
8.90
Clinical
Reported OS
28.25
Clinical
Result source
ClinicalTrials.gov NCT03361748
Clinical
Program phase
PHASE_2
Clinical
Trial ref
NCT03361748